Terbinafine Hydrochloride 1% cream – Summary of Product Characteristics (SmPC) for healthcare professionals

1. NAME OF THE MEDICINAL PRODUCT

Terbinafine Hydrochloride 1% cream

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

10 mg terbinafine hydrochloride (equivalent to 8.89 mg terbinafine) in 1 g cream.

Excipients with known effect: 40 mg cetyl alcohol, 40 mg cetostearyl alcohol and 10 mg benzyl alcohol in 1 g cream.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Cream.

White or almost white cream, with slight almond odour.

4.

4.1 Therapeutic indications

Fungal infections of the skin caused by Trichophyton (e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum.

Yeast infections of the skin, principally those caused by the genus Candida (eg. C. albicans).

Pityriasis (tinea) versicolor due to Pityrosporum orbiculare (also known as Malassezia furfur).

4.2 Posology and method of administration

Posology

Terbinafine cream can be applied once or twice daily.

The duration of treatment depends on the indication and severity of infection.

The likely durations of treatment are as follows:

Tinea corporis, cruris: 1 to 2 weeks

Tinea pedis: 1 week

Cutaneous candidiasis: 2 weeks

Pityriasis versicolor: 2 weeks

Relief of clinical symptoms usually occurs within a few days. Irregular use or premature discontinuation of treatment carries the risk of recurrence. If there are no signs of improvement after two weeks, the diagnosis should be verified.

Paediatric population

The experience with topical terbinafine in children is still limited and its use cannot therefore be recommended.

Elderly

There is no evidence to suggest that older patients require different dosages or experience side-effects different to those of younger patients.

Method of administration

Via the topical route.

Cleanse and dry the affected areas thoroughly before application of Terbinafine cream. Apply the cream to the affected skin and surrounding area in a thin layer and rub in lightly. In the case of intertriginous infections (submammary, interdigital, intergluteal, inguinal), the application may be covered with a gauze strip, especially at night. Ensure that new gauze is used after each application if required.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Terbinafine cream is for external use only.

It may be irritating to the eyes. In case of accidental contact with the eyes, rinse eyes thoroughly with running water and contact an ophthalmologist if necessary.

Terbinafine cream should be kept out of the sight and reach of children.

This medicinal product contains cetyl alcohol and cetostearyl alcohol, which may cause local skin reactions (e.g. contact dermatitis).

This medicinal product contains 10 mg benzyl alcohol in each gram of cream. Benzyl alcohol may cause allergic reactions and mild local irritation.

4.5 Interaction with other medicinal products and other forms of interaction

No drug interactions are known with the topical forms of terbinafine.

4.6 Fertility, pregnancy and lactation

Pregnancy

There is no clinical experience with Terbinafine cream in pregnant women. Foetal toxicity studies in animals suggest no adverse effects (see section 5.3).

Terbinafine cream should not be used during pregnancy unless clearly necessary.

Breast-feeding

Terbinafine is excreted in breast milk. Terbinafine cream should not be used during breast-feeding. In addition, infants must not be allowed to come into contact with any treated skin, including the breast.

Fertility

No effect of terbinafine on fertility has been seen in animal studies (see section 5.3).

4.7 Effects on ability to drive and use machines

Terbinafine cream has no influence on the ability to drive and use machines.

4.8 Undesirable effects

Local symptoms such as pruritus, skin exfoliation, application site pain, application site irritation, pigmentation disorder, skin burning sensation, erythema, scab, etc. may occur at the site of application. These harmless symptoms must be distinguished from hypersensitivity reactions including rash, which are reported in sporadic cases and require discontinuation of therapy.

In case of accidental contact with the eyes terbinafine may be irritating to the eyes.

In rare cases, the underlying fungal infection may be aggravated.

Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10); common (≥ 1/100 to <1/10); uncommon (≥1/1,000 to < 1/100); rare (≥1/10,000 to <1/1,000); very rare (< 1/10,000), or not known (can not to be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Immune system disorders

Not known Hypersensitivity*

Eye disorders

Rare Eye irritation

Skin and subcutaneous tissue disorders

Common Skin exfoliation, pruritus

Uncommon Skin lesion, scab, skin disorder, pigmentation disorder, erythema, skin burning sensation Rare Dry skin, dermatitis contact, eczema

Not known Rash*

General disorders and administration site conditions

Uncommon Pain, application site pain, application site irritation

Rare Condition aggravated

*: Based on post-marketing experience

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Terbinafine cream is for external use only. The low systemic absorption of topical terbinafine renders overdose extremely unlikely.

Accidental ingestion of one 30 g tube of terbinafine cream, which contains 300 mg terbinafine hydrochloride, is comparable to ingestion of one terbinafine 250 mg tablet (adult oral unit dose).

Symptoms

Should a larger amount of terbinafine cream be inadvertently ingested, adverse effects similar to those observed with an overdosage of terbinafine tablets are to be expected. These include headache, nausea, epigastric pain and dizziness.

Treatment

If accidentally ingested, the recommended treatment of overdosage consists of eliminating the active substance, primarily by the administration of activated charcoal, and giving symptomatic supportive therapy if needed.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antifungals for dermatological use, Other antifungals for topical use; ATC code: D01AE15

Terbinafine is an allylamine, which has a broad-spectrum of anti-fungal activity. At low concentrations terbinafine is fungicidal against dermatophytes, moulds and certain dimorphic fungi. The activity against yeasts is fungicidal or fungistatic depending on the species.

Terbinafine interferes specifically with fungal sterol biosynthesis at an early step. This leads to a deficiency in ergosterol and to an intracellular accumulation of squalene, resulting in fungal cell death. Terbinafine acts by inhibition of squalene epoxidase in the fungal cell membrane. The enzyme squalene epoxidase is not linked to the cytochrome P450 system.

Terbinafine is used for the treatment of fungal infections of the skin and nails, which is caused by Trichophyton (e.g. T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum. The following table outlines the range of minimum inhibitory concentrations (MIC) against the dermatophytes.

5.2 Pharmacokinetic properties

Absorption

Less than 5% of the dose is absorbed after topical application; systemic exposure is therefore very slight.

5.3 Preclinical safety data

In long-term studies (up to 1 year) in rats and dogs no marked toxic effects were seen in either species up to oral doses of about 100 mg/kg a day. At high oral doses, the liver and possibly also the kidneys were identified as potential target organs.

In a two-year oral carcinogenicity study in mice, no neoplastic or other abnormal findings attributable to treatment were made up to doses of 130 mg/kg (males) and 156 mg/kg (females) a day. In a two-year oral carcinogenicity study in rats at the highest dose level, 69 mg/kg a day, an increased incidence of liver tumours was observed in males. The changes, which may be associated with peroxisome proliferation, have been shown to be species-specific since they were not seen in the carcinogenicity study in mice or in other studies in mice, dogs or monkeys.

During the studies of high dose oral terbinafine in monkeys, refractile irregularities were observed in the retina at the higher doses (non-toxic effect level was 50 mg/kg). These irregularities were associated with the presence of a terbinafine metabolite in ocular tissue and disappeared after drug discontinuation. There were no associated histological changes.

A standard battery of in vitro and in vivo genotoxicity tests revealed no evidence of a mutagenic or clastogenic potential for the drug.

No adverse effects on fertility or other reproduction parameters were observed in studies in rats or rabbits.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium hydroxide,

Benzyl alcohol,

Sorbitan stearate,

Cetyl palmitate,

Cetyl alcohol,

Cetostearyl alcohol,

Polysorbate 60,

Isopropyl myristate,

Water purified.

6.2 Incompatibilities

None known.

6.3 Shelf life

4 years

Shelf life after opening: 1 month

6.4 Special precautions for storage

No special precautions for storage.

Store in original container.

6.5 Nature and contents of container

Aluminium tube closed by polyethylene cap. The tubes are containing 7.5 g, 15 g or 30 g cream.

6.6 Special precautions for disposal

No special instructions.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

Gedeon Richter Plc.

H-1103 Budapest

Gyömrői út 19-21

Hungary

8 MARKETING AUTHORISATION NUMBER(S)

PL 04854/0043

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

Date of first authorisation: 13/09/2011

10 DATE OF REVISION OF THE TEXT

22/05/2020